 |
|
T-Lymphocyte Interferon- Receptor Binding in Patients With Myasthenia Gravis
Paolo Bongioanni, MD, PhD;
Roberta Ricciardi, MD;
Maria Rosaria Romano, BS
Arch Neurol. 1999;56:933-938.
Objective To investigate some aspects of T-lymphocyte–dependent immune function in patients with myasthenia gravis (MG).
Design Assay interferon- binding on T lymphocytes from patients with MG compared with healthy controls.
Setting The study was performed on ambulatory patients in a tertiary care center, where MG was diagnosed according to Osserman criteria.
Patients Thirty-six patients with MG (19 women and 17 men; mean±SD age, 50.2±17.6 years) were selected consecutively. They were assigned to groups 1, 2A, and 2B. Ten patients were treated with pyridostigmine bromide alone, 18 were treated with pyridostigmine and corticosteroids, and 8 were not yet treated. Thirty-six age- and sex-matched healthy nonsmoking subjects formed the control group.
Results A significant (P<.001) decrease of T-lymphocyte interferon- binding was found in patients with MG compared with healthy controls (483±14 vs 734±13 receptors [SEM] per cell), whereas the ligand-receptor affinity values [SEM] were similar in the 2 groups (0.9±0.05 and 1.0±0.07 nmol/L).
Conclusion These data indicate a persistent activation of the immune system in patients with MG, since reduced cell surface interferon- receptors seem to be related with enhanced T-lymphocyte immune function.
From the Department of Neurosciences, Section of Neurology, Institute of Clinical Medicine, University of Pisa, Pisa, Italy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(8):1037-1038.
FULL TEXT
|
